InsidersTradesSigma
Follow the FULCRUM THERAPEUTICS INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €293.7m. The latest transaction was filed on 26 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ALAN EZEKOWITZ. The full history is accessible without an account.
Analysts rate FULCRUM THERAPEUTICS INC Hold (neutral), based on 4 analysts. Average price target: US$3.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
FULCRUM THERAPEUTICS INC es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades genéticas. Emplea enfoques innovadores para atacar mecanismos de enfermedades específicos.